20 completed, 13 recruiting, 7 active not recruiting, 7 unknown. 60 Phase 2, 8 Phase 1, 1 Phase 3.
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| An Experimental Study of Belzutifan Impact on Catecholamine Metabolism Belzutifan - Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant | Phase 2 | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 12 | 2026-04-27 | 2026-07-02 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma ONC206, ONC206: Dose 1, ONC206: Dose 2 - Advanced Pheochromocytoma and Paraganglioma, PCPG | Phase 2 | Recruiting | Jazz Pharmaceuticals | 90 | 2026-01-02 | 2026-10-29 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-10-29 |
| Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma Anlotinib and Benmelstobart - Pheochromocytoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 22 | 2025-05-01 | 2025-04-29 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System 18F-mFBG - Neuroblastoma, Pheochromocytoma | Phase 2 | Withdrawn | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2025-01-01 | 2025-01-21 | |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial Belzutifan - Von Hippel Lindau, Von Hippel Lindau Disease | Phase 2 | Recruiting | José Claudio Casali da Rocha | 100 | 2024-01-01 | 2025-09-11 |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors [203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-09-27 | 2026-10-13 |
| "Receptor Radionuclide Therapy With 177Lu-DOTATOC 177Lu-DOTATOC - Neuroendocrine Tumors, Paraganglioma | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 100 | 2023-09-13 | 2024-08-13 |
| HTL0039732 in Participants With Advanced Solid Tumours HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 150 | 2023-08-02 | 2026-10-01 |
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment Penpulimab - Pheochromocytoma, Metastatic, Pheochromocytoma Malignant | Phase 2 | Unknown | Peking Union Medical College Hospital | 5 | 2023-04-01 | 2023-06-02 |
| A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL Temozolomide - Pheochromocytoma, Paraganglioma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2023-04-01 | 2023-06-01 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma | Phase 2 | Active not recruiting | Advanced Accelerator Applications | 11 | 2022-08-31 | 2026-02-12 |
| A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL Anlotinib hydrochloride - Pheochromocytoma, Paraganglioma | Phase 2 | Unknown | Peking Union Medical College Hospital | 10 | 2022-05-01 | 2023-05-31 |
| A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial Anlotinib - Advanced or Metastatic Paraganglioma/ Pheochromocytoma | Phase 2 | Unknown | Nanjing First Hospital, Nanjing Medical University | 20 | 2021-09-14 | 2021-11-24 |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) Belzutifan - Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 355 | 2021-08-12 | 2026-10-21 |
Showing 20 of 60. Sign in to see all of them.
Pheochromocytoma (55) · Neuroendocrine Tumors (14) · Neoplasm Metastasis (8) · Neoplasms (7) · Paraganglioma, Extra-Adrenal (6) · Adrenocortical Carcinoma (5) · Carcinoma, Medullary (5) · Carcinoma, Renal Cell (5) · Neuroblastoma (5) · Sarcoma (5) · Somatostatinoma (5) · Carcinoid Tumor (4) · Head and Neck Neoplasms (4) · Kidney Neoplasms (4)
Neoplasms by Histologic Type (60) · Neoplasms, Germ Cell and Embryonal (60) · Neoplasms, Nerve Tissue (60) · Neuroectodermal Tumors (60) · Neoplasms (53) · Neuroendocrine Tumors (46) · Neoplasms, Glandular and Epithelial (26) · Neoplasms by Site (22) · Adenocarcinoma (19) · Carcinoma (19) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Digestive System Diseases (13) · Digestive System Neoplasms (13)
lutetium Lu 177 dotatate (6) · 3-Iodobenzylguanidine (5) · Temozolomide (4) · anlotinib (4) · Magnetic Resonance Spectroscopy (3) · belzutifan (3) · gallium Ga 68 dotatate (3) · 177Lu-octreotide, DOTA(0)-Tyr(3)- (2) · Axitinib (2) · Everolimus (2) · Nivolumab (2) · Radiotherapy (2) · Specimen Handling (2) · Sunitinib (2) · cabozantinib (2)
National Cancer Institute (NCI) (11) · Peking Union Medical College Hospital (5) · M.D. Anderson Cancer Center (4) · University of California, San Francisco (3) · Columbia University (2) · Molecular Insight Pharmaceuticals, Inc. (2) · Abramson Cancer Center at Penn Medicine (1) · Advanced Accelerator Applications (1) · Antonio Fojo (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Cancer Research UK (1) · Dana-Farber Cancer Institute (1) · Delcath Systems Inc. (1) · Enterome (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
United States (39) · China (9) · Spain (5) · France (4) · Italy (4) · Netherlands (4) · United Kingdom (4) · Canada (3) · Germany (3) · Denmark (2) · Poland (2) · Singapore (2) · South Korea (2) · Sweden (2) · Australia (1)
Anli Tong (5) · Camilo Jimenez (2) · Frank I Lin, M.D. (2) · Afshin Shafie, MD (1) · Alice Lee, MD (1) · Andrea B Apolo, M.D. (1) · Antonio Fojo, MD (1) · Antonio Fojo, MD, PhD (1) · Ashish Chintakuntlawar (1) · Aung Naing (1) · Ayman Gaber, MD (1) · Bennett Chin, MD (1) · Camillo Jimenez, MD (1) · Christine A Pratilas (1) · Daniel Pryma, MD (1)
PMID 19636009, PMID 24952730, PMID 26040622, PMID 26742708, PMID 26773712, PMID 29099942, PMID 31322702, PMID 31533818, PMID 31969335, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33362722, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33551992, PMID 33770291, PMID 33882143, PMID 34241781, PMID 34380663, PMID 34716198, PMID 34725215, PMID 35618285, PMID 35999229, PMID 36302175, PMID 36472300, PMID 37568622, PMID 37886645, PMID 38243705, PMID 38358334, PMID 38402886, PMID 38608693, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39500789, PMID 39583952, PMID 39856213, PMID 40198358, PMID 40212844, PMID 40402690, PMID 40588371, PMID 41124218, PMID 41143139, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42342409, PMID 42499790
2023 (2), P30CA015083 (2), 2019 (1), N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), U10CA180821 (1), U10CA180886 (1), U10CA180888 (1)